INBS
Intelligent Bio Solutions Inc.
There isn't enough reported data to score INBS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
INBS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
INBS's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
INBS PE Valuation
INBS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
INBS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect INBS's losses to grow, with revenue declining.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
INBS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$8.95 | +$7.55 |
| Q2 2026 | -$11.59 | +$8.41 |
| Q3 2023 | -$1,384.80 | -$84.71 |
| Q2 2023 | -$1,452.00 | -$103.91 |
| Q1 2023 | -$1,273.69 | -$92.14 |
| Q4 2022 | -$803.29 | +$810.26 |
| Q3 2022 | -$1,300.09 | +$313.46 |
INBS is still losing money, but far less than before: $8.95 per share over the past year, against $1,613.55 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over INBS on earnings quality, reporting a profit while its opponent remains loss making.
INBS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4M | +25% |
| Q2 2026 | $1.1M | +36% |
| Q1 2026 | $1.1M | +18% |
| Q4 2025 | $896.8K | +21% |
| Q3 2025 | $1.1M | +11% |
| Q2 2025 | $843.9K | +16% |
| Q1 2025 | $902.1K | +9.5% |
| Q4 2024 | $741.1K | -3% |
INBS's revenue has grown year over year for seven quarters in a row: $1M last quarter, up 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -193% | +77 points |
| Q2 2026 | -346% | +21 points |
| Q1 2026 | -278% | +5.2 points |
| Q4 2025 | -294% | +12 points |
| Q3 2025 | -270% | +3.2 points |
| Q2 2025 | -368% | +19 points |
| Q1 2025 | -283% | +76 points |
| Q4 2024 | -306% | -45 points |
INBS's operating margin was −193% last quarter, up 77 points from the same quarter a year ago, near the top of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over INBS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over INBS on profitability, with a higher operating margin.
INBS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.3M | -$1.6M |
| Q4 2025 | -$1.6M | +$689K |
| Q3 2025 | -$2.9M | -$530K |
| Q1 2025 | -$2.8M | -$308.8K |
| Q4 2024 | -$2.3M | +$544.4K |
| Q3 2024 | -$2.4M | -$1.1M |
| Q2 2024 | -$2.9M | -$2.4M |
| Q1 2024 | -$2.4M | +$71.9K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with INBS at down 50%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
INBS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +94% | +1.5M shares |
| 1 year | +436% | +2.5M shares |
| 3 years | +50551% | +3.1M shares |
INBS has 3M diluted shares, up 436% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over INBS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
INBS Net Leverage
INBS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
INBS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.1 | Neutral |
| Stochastic | 25.1 | Neutral |
INBS's weekly RSI is 42 (neutral) and its Stochastic is 25 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
INBS PE vs Healthcare Sector
INBS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
INBS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.71 | 13% above |
| 20 week MA | $1.98 | 2.5% below |
| 50 week MA | $3.82 | 49% below |
| 100 week MA | $9.38 | 79% below |
| 200 week MA | $95.8 | 98% below |
INBS has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 98% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over INBS on trend strength, trading above more of its moving averages.
INBS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $25,320.0 | $25,320.0 | 0% |
| 2021 | $25,320.0 | $3,864.0 | -85% |
| 2022 | $3,864.0 | $686.0 | -82% |
| 2023 | $686.0 | $40.6 | -94% |
| 2024 | $40.6 | $14.3 | -65% |
| 2025 | $14.3 | $4.84 | -66% |
| 2026 YTD | $4.84 | $1.93 | -60% |
INBS has finished every year since 2020 lower, and it's down 60% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over INBS on returns for 2026, with the stronger performance.